Skip to main content

Advertisement

SpringerLink
Log in

Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

All currently available and approved therapies for osteoporosis inhibit bone resorption. But, despite their great value, antiresorptive agents are generally not associated with dramatic increases in bone mass. In light of these data, the aim of our prospective, placebo-controlled, randomized clinical trial, with a 3-year follow up, was to examine the effects of cyclic intravenous pamidronate and fluoride in combination, versus pamidronate alone, on bone mineral density (BMD) at vertebral and femoral levels, biochemical markers of bone turnover, IGF-1 serum levels, and safety and tolerability in 40 postmenopausal women with osteoporosis. During the treatment period, pamidronate alone reduced both markers of bone formation and bone resorption, resulting in an increase of BMD, after 3 years, of 7.07% at the lumbar level and of 6.76% at the femoral level. In the group treated with pamidronate and fluoride, markers of bone turnover had a different trend: after 3 years, there was a lower reduction of bone resorption and an increase of bone formation markers, with a concomitant increase in IGF-1 levels. This resulted, after 3 years of treatment, in a marked variation of BMD at the lumbar level (+12.74%) and a reduced, but still significant, increase at the femoral level (3.89%). Spine radiography and clinical evaluation did not reveal any vertebral fractures in either treatment group. In conclusion, the combined use of pamidronate and fluoride produced somewhat larger, continuous increases in BMD, at the lumbar level, than pamidronate alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437–1443

    Google Scholar 

  2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 348: 1535–1541

    Google Scholar 

  3. Orr-Walker B, Wattie DJ, Evans MC, Reid IR (1997) Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. Clin Endocrinol (Oxf) 46:87–92

    Google Scholar 

  4. Devogelaer JP, Nagant de Deuxchaisnes C (1997) Use of pamidronate in chronic and acute bone loss conditions. Medicina (B Aires) 57:101–108

    Google Scholar 

  5. Parisi MS, Oliveri MB, Mautalen CA (2001) Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia. J Clin Densitom 4: 167–172

    Google Scholar 

  6. Heaney RP (1994) The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 9:1515–1523

    Google Scholar 

  7. Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC II (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291–297

    Google Scholar 

  8. Goziotis A, Sukhu B, Torontali M, Dowhaniuk M, Tenenbaum HC (1995) Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone 16:317S–327S

    Google Scholar 

  9. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC (2000) Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60:6001–6007

    Google Scholar 

  10. Erdtsieck RJ, Pols HA, Valk NK, van Ouwerkerk BM, Lamberts SW, Mulder P, Birkenhager JC (1995) Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Clin Endocrinol (Oxf) 43:557–565

    Google Scholar 

  11. Ringe JD, Rovati LC (2001) Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 69:252–255

    Google Scholar 

  12. Farley JR, Wergedal JE, Baylink DJ (1983) Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science 222:330–332

    Google Scholar 

  13. Reed BY, Zerwekh JE, Antich PP, Pak CY (1993) Fluoride-stimulated [3H]thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor beta. J Bone Miner Res 8:19–25

    Google Scholar 

  14. Pak CY, Zerwekh JE, Antich P (1995) Anabolic effects of fluoride on bone. Trends Endocrinol Metab 6:229–234

    Google Scholar 

  15. Lau KH, Baylink DJ (1998) Molecular mechanism of action of fluoride on bone cells. J Bone Miner Res 13:1660–1667

    Google Scholar 

  16. Thiébaud D, Burckhardt P, Melchior J, Eckert P, Jacquet AF, Schnyder P, Gobelet C (1994) Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 4:76–83

    Google Scholar 

  17. Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP (2001) Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 16:104–112

    Google Scholar 

  18. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS (2001) Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948–955

    Google Scholar 

  19. Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer DG, Thiebaud D, Burckhardt P (2001) Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 12:112–116

    Google Scholar 

  20. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990) Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809

    Google Scholar 

  21. Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, Prost A, Zeigler G, Netter P (1988) Risk-benefit ratio of sodium fluoride in primary vertebral osteoporosis. Lancet 2:361–365

    Google Scholar 

  22. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR (1995) Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med 123:401–408

    Google Scholar 

  23. Pak CY, Adams-Huet B, Sakhaee K, Bell NH, Licata A, Johnston C, Rubin B, Bonnick S, Piziak V, Graham H, Ballard J, Berger R, Fears W, Breslau N, Rubin C (1996) Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis. J Bone Miner Res 11:160–168

    Google Scholar 

  24. Farrerons J, Rodriguez de la Serna A, Guanabens N, Armadans L, Lopez-Navidad A, Yoldi B, Renau A, Vaque J (1997) Sodium fluoride treatment is a major protector against vertebral and nonvertebral fractures when compared with other common treatments of osteoporosis: a longitudinal, observational study. Calcif Tissue Int 60:250–254

    Google Scholar 

  25. Haguenauer D, Welch V, Shea B, Tugwell P, Adachi JD, Wells G (2000) Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int 11:727–738

    Google Scholar 

  26. Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS (2001) Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 161:2325–2333

    Google Scholar 

  27. Reginster JY, Rovati LC, Setnikar I (2001) Correct regimen of fluoride and calcium reduces the risk of vertebral fractures in postmenopausal osteoporosis. Osteoporos Int 12:800

    Google Scholar 

  28. Minne HW, Leidig G, Wuster C, Siromachkostov L, Baldauf G, Bickel R, Sauer P, Lojen M, Ziegler R (1988) A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Miner 3:335–349

    Google Scholar 

  29. World Health Organization Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843

  30. Valkema R,Vismans FJFE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM (1989) Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 5:183–192

    Google Scholar 

  31. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J (1994) Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595–1599

    Google Scholar 

  32. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–1480

    Google Scholar 

  33. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694

    Google Scholar 

  34. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109–3115

    Google Scholar 

  35. Chavassieux PM, Arlot ME, Roux JP, Portero N, Daifotis A, Yates AJ, Hamdy NA, Malice MP, Freedholm D, Meunier PJ (2000) Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res 15:754–762

    Google Scholar 

  36. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185–191

    Google Scholar 

  37. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282:1344–1352

    Google Scholar 

  38. Bravenboer N, Papapoulos SE, Holzmann P, Hamdy NA, Netelenbos JC, Lips P (1999) Bone histomorphometric evaluation of pamidronate treatment in clinically manifest osteoporosis. Osteoporos Int 9:489–493

    Google Scholar 

  39. Chapurlat RD, Delmas PD, Liens D, Meunier PJ (1997) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746–1752

    Google Scholar 

  40. Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT, Boyce BF (1993) Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 342:1459–1460

    Google Scholar 

  41. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620

    Google Scholar 

  42. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531

    Google Scholar 

  43. Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69:281–286

    Google Scholar 

  44. Kodama Y, Nakayama K, Fuse H, Fukumoto S, Kawahara H, Takahashi H, Kurokawa T, Sekiguchi C, Nakamura T, Matsumoto T (1997) Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J Bone Miner Res 12:1058–1067

    Google Scholar 

  45. Bourrin S, Ammann P, Bonjour JP, Rizzoli R (2002) Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 30:195–200

    Google Scholar 

  46. Zerwekh JE, Antich PP, Sakhaee K, Prior J, Gonzales J, Gottschalk F, Pak CY (1992) Lack of deleterious effect of slow-release sodium fluoride treatment on cortical bone histology and quality in osteoporotic patients. Bone Miner 18:65–76

    Google Scholar 

  47. Kragstrup J, Shijie Z, Mosekilde L, Melsen F (1989) Effects of sodium fluoride, vitamin D, and calcium on cortical bone remodeling in osteoporotic patients. Calcif Tissue Int 45:337–341

    Google Scholar 

  48. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, Cedel SL, Melton LJ III (1990 Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 322:802–809

    Google Scholar 

  49. Gutteridge DH, Boivin G, Meunier PJ (1990) Fluoride in postmenopausal osteoporosis: selective increase in external cortical porosity correlates with cancellous volume increase without change in cortical bone volume. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Osteopress, Copenhagen, pp 718–720

  50. Pak CY, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K (1989) Safe and effective treatment of osteoporosis with intermittent slow-release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 68:150–159

    Google Scholar 

  51. Pak CY, Sakhaee K, Piziak V, Peterson RD, Breslau NA, Boyd P, Poindexter JR, Herzog J, Heard-Sakhaee A, Haynes S (1994) Slow-release sodium fluoride in the management of postmenopausal osteoporosis. a randomized controlled trial. Ann Intern Med 120:625–632

    Google Scholar 

  52. Pak CY, Sakhaee K, Parcel C, Poindexter J, Adams B, Bahar A, Beckley R (1990) Fluoride bioavailability from slow-release sodium fluoride given with calcium citrate. J Bone Miner Res 5:857–862

    Google Scholar 

  53. Rechler MM, Nissley SP (1990) Insulin-like growth factors. In: Sporn MB, Roberts AB (eds) Peptide growth factors and theirs receptors. Springer, Berlin Heidelberg New York, pp 263–346

  54. Hock JM, Centrella M, Canalis E (1988) Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 122:254–260

    Google Scholar 

  55. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrin Rev 16:3–34

    Google Scholar 

  56. Turner CH, Garetto LP, Dunipace AJ, Zhang W, Wilson ME, Grynpas MD, Chachra D, McClintock R, Peacock M, Stookey GK (1997) Fluoride treatment increased serum IGF-1, bone turnover, and bone mass, but not bone strength, in rabbits. Calcif Tissue Int 61:77–83

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Palazzo Forte Gonzaga, via Montepiselli 71, 98100, Messina, Italy

    N. Morabito

  2. Department of Internal Medicine, University of Messina, Messina, Italy

    N. Morabito, A. Gaudio, A. Lasco, C. Vergara, F. Tallarida, A. Trifiletti, M. Cincotta, M. A. Pizzoleo & N. Frisina

  3. Institute of Biochemistry, University of Messina, Messina, Italy

    G. Crisafulli

Authors
  1. N. Morabito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Gaudio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Lasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Vergara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Tallarida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Crisafulli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Trifiletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Cincotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. A. Pizzoleo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. N. Frisina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Morabito.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morabito, N., Gaudio, A., Lasco, A. et al. Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporos Int 14, 500–506 (2003). https://doi.org/10.1007/s00198-003-1397-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-003-1397-0

Keywords

Search

Navigation